Abstract
Objective
The human gut fungal community, known as the mycobiome, plays a fundamental role in the gut ecosystem and health. Here we aimed to investigate the determinants and long-term stability of gut mycobiome among middle-aged and elderly adults. We further explored the interplay between gut fungi and bacteria on metabolic health.
Design
The present study included 1244 participants from the Guangzhou Nutrition and Health Study. We characterised the long-term stability and determinants of the human gut mycobiome, especially long-term habitual dietary consumption. The comprehensive multiomics analyses were performed to investigate the ecological links between gut bacteria, fungi and faecal metabolome. Finally, we examined whether the interaction between gut bacteria and fungi could modulate the metabolic risk.
Results
The gut fungal composition was temporally stable and mainly determined by age, long-term habitual diet and host physiological states. Specifically, compared with middle-aged individuals, Blastobotrys and Agaricomycetes spp were depleted, while Malassezia was enriched in the elderly. Dairy consumption was positively associated with Saccharomyces but inversely associated with Candida. Notably, Saccharomycetales spp interacted with gut bacterial diversity to influence insulin resistance. Bidirectional mediation analyses indicated that bacterial function or faecal histidine might causally mediate an impact of Pichia on blood cholesterol.
Conclusion
We depict the sociodemographic and dietary determinants of human gut mycobiome in middle-aged and elderly individuals, and further reveal that the gut mycobiome may be closely associated with the host metabolic health through regulating gut bacterial functions and metabolites.
Keywords: intestinal microbiology, molecular epidemiology
Significance of this study.
What is already known on this subject?
The human gut fungal community, known as the mycobiome, is integral to the gut ecosystem and of putative health consequence.
The composition and long-term stability of the gut mycobiome in middle age and later life are not known.
What are the new findings?
Considerable gut fungal composition is temporally stable while modulated by age, long-term habitual diet and host physiological states.
The gut mycobiome is interdependent on bacterial taxonomy and function, where Saccharomycetales spp may interact with gut bacterial diversity to influence insulin resistance.
Bidirectional mediation analyses indicate that bacterial function or faecal histidine may causally mediate an impact of gut fungi on blood cholesterol.
How might it impact on clinical practice in the foreseeable future?
Gut mycobiome features may be new interventions or therapeutic targets for human metabolic diseases.
Introduction
Fungi, as eukaryotes, are ancestrally and ecologically intrinsic to terrestrial life with multiple roles, extending to the regulobiotic.1–3 As we appreciate more and more how socioecological we are, the place of fungi in our biology and health is increasingly evident.3 4 The human gut fungal community,5 6 referred to as the gut mycobiome,7 comprises less than 0.1% of the microbial cells in the gut ecosystem,8 but changes in its composition are linked to a number of diseases including IBD, IBS and colorectal cancer.9 Geography, urbanisation, ethnicity and diet play a role in shaping the gut mycobiome composition.6 10 11 While the gut mycobiome may be individual-specific, it may undergo age-associated and personal behaviourally related changes.12 13 Presently, little is known about the profiles and long-term stability of the gut mycobiome among adults as they age.
Gut bacteria are associated with human metabolic diseases like type 2 diabetes,14 hypertension15 and obesity.16 The gut fungal and bacterial communities are unavoidably connected and likely to influence each other in various ways which interdigitate with host metabolic pathways. The modes of cross-kingdom interaction include mutualism, commensalism, amensalism, parasitism and competition.7 These may be affected by physical association, molecular dialogue and an environmental milieu constituted by gut ecology.17 This ecosystem subserves the functionality of the colorectum in transiting food residue, fermentation and nourishing the gut itself. While some associations between the gut mycobiome and metabolic disease have been reported in animal models18 19 and in limited human studies,20 21 the potential for gut fungal and bacterial cohabitation to modulate metabolic health in humans remains unclear.
In this study, we have profiled gut fungal and bacterial community structure and the faecal metabolome in a population-based Guangzhou Nutrition and Health Study (GNHS) cohort in China (n=1244). We then characterised the long-term stability and determinants of the fungal community among these middle-aged and elderly adults. To gain biological insight, we examined the ecological links between gut fungi, bacteria and the faecal metabolome. Finally, we hypothesised that gut fungi could interact with bacteria to modulate metabolic health.
Results
Composition and long-term stability of the human gut mycobiome
We studied 1244 participants with a mean age of 64.9 years as a subset of the GNHS cohort (online supplemental figures S1 and S2A and online supplemental table S1). Based on the internal transcribed spacer 2 (ITS2) sequences, a taxonomic profile of the gut mycobiome was determined (online supplemental figure S1). There was a total of 204 gut fungal genera (online supplemental tables S2 and S3) where Ascomycota, Basidiomycota and unclassified Fungi sp were the most dominant phyla with a mean relative abundance of 77.0%, 5.7% and 17.0%, respectively (figure 1A–C). After 5% prevalence filtering, 26 gut fungal genera were identified as a group of core taxa, including Saccharomyces, Candida, Aspergillus, Malassezia, etc (figure 1A and online supplemental table S3). Through literature review, we showed that these gut fungal genera might have potential environmental determinants or sources (online supplemental table S4). We found similar abundance ratios of Ascomycota to Basidiomycota in the discovery GNHS cohort as in the Human Microbiome Project cohort12 and the Danish cohort22 (online supplemental figure S2B). Some genera were consistently present, with 40 genera detected in all three cohorts (online supplemental figure S2C and online supplemental table S5).
gutjnl-2021-326298supp001.pdf (3MB, pdf)
gutjnl-2021-326298supp002.xlsx (1.3MB, xlsx)
Long-term stability of the gut mycobiome was determined in follow-up after ~3.2 years in 184 participants (online supplemental table S6) with ITS2 fungal data that showed non-significant alterations over time in 11 genera of the Ascomycota (eg, Pichia, Alternaria and Wickerhamiella) (figure 1D and online supplemental table S7), which indicates that the relative abundances of these genera were temporally stable. Saccharomyces, Candida and Aspergillus were abundant at baseline and remained the most prevalent taxa at the follow-up visit (online supplemental figure S3A, B). There were seven core fungal genera repeatedly detected in the same individual at both time points in over 40% of the participants (online supplemental figure S3C). For the dominant fungal phyla, this probability was over 85%. However, eight genera had a significant increased change in relative abundance, Penicillium and Candida being examples, while 5 out of 26 genera showed a decreased abundance (paired Wilcoxon test, q<0.05) (online supplemental table S7). These changes may be partly attributable or contribute to increasing age, as in a metagenomic study with age-associated alterations in the gut mycobiome, particularly Aspergillus and Penicillium.13
Compared with gut bacteria, the gut mycobiome has sparser characteristics. Gut bacterial composition was profiled using the 16S rRNA sequencing for 1244 participants. The gut bacteria had a larger α-diversity than gut fungi (online supplemental figure S4A), which was similar to other microbiomic reports in healthy individuals.12 23 However, gut mycobiome composition varied greatly between individuals (online supplemental figure S4B), suggesting that gut fungi may be more personalised.
Determinants of variation in gut mycobiome structure
Procrustes analysis revealed a strong correlation between the data matrix of the gut fungi and bacteria (p=0.009) (online supplemental figure S5). There were negative associations for most of the α-diversity indices between the two kingdoms (figure 2A), suggesting the ecobalance between gut fungal and bacterial community. At the genus level, five were identified as the top contributors to the gut fungal community variation, including Saccharomyces, Candida and Aspergillus, followed by Alternaria and Blastobotrys (figure 2B).
We correlated 7 demographic factors, 14 physiological traits, 16 dietary intakes and 3 diseases with the overall variation in the gut mycobiome. Age, dairy intake and total cholesterol were significantly associated with the gut fungal composition at a nominal p value of <0.05 (Bray-Curtis distance, PERMANOVA) (figure 2C and online supplemental table S8). Age had the largest explanatory power for the interindividual variation in gut mycobiome, which further suggests that some fungal taxa alter with time. For instance, compared with middle-aged participants, Blastobotrys and Agaricomycetes spp were depleted, while Malassezia was enriched in the elderly (p<0.05, online supplemental table S9). Spearman correlation analysis was used to examine the association between fungal α-diversity and host factors. None of the signals surpassed the conservative threshold of q<0.05. Notwithstanding, gut fungal richness was positively associated with the total energy intake, various fruits consumption and Bristol stool scale, and was negatively associated with smoking status at a nominal p value of <0.05 (online supplemental figure S6). The patterns of significance for different factors varied among middle-aged and elderly participants with total energy intake positively associated with fungal α-diversity in middle-aged individuals but not in the elderly (online supplemental figure S6).
We then investigated the links between long-term habitual dietary intakes and the gut mycobiome. The multivariable linear regression models indicated that habitual diet may be an important determinant of the mycobiome with most foods associated positively or negatively with specific fungi. The only foods not significantly associated with fungi were fruits and fish. For instance, dairy intake was positively associated with Saccharomyces and Meyerozyme but inversely associated with Candida (p<0.05) (figure 2D).
Ecological connectedness of gut fungi and bacteria
To explore the ecological links between gut fungi and bacteria, the Sparse Correlations for Compositional data (SparCC) algorithm was applied to construct the interkingdom and intrakingdom association networks. A total of 6346 significant associations were identified and 3538 were validated by the Spearman correlation analysis (q<0.05, online supplemental figure S7A), suggesting extensive taxonomic associations between gut fungi and bacteria. However, only 134 associations were cross-kingdom associations (online supplemental figure S7B), which indicates potentially greater intrakingdom communication than cross-kingdom. However, given the evolutionary resilience and ecological dominance of fungi, their regulobiotic position may be disproportionately consequential.
The association between fungi and bacteria was highly variable in taxonomy (figure 3A). The positive correlation of some bacteria (Bifidobacterium and Veillonella) with fungi (Blumeria and Saccharomyces) suggests that there may be a codependence for both microbes. The inverse correlation of other bacteria (Butyricimonas and Alistipes) with fungi (Hanseniaspora and Wickerhamiella) suggests that there may be competitive or inhibitory actions (q<0.05; figure 3A and online supplemental table S9). When α-diversity of the gut bacteria was considered, significant correlations were found with specific fungal taxa (online supplemental figure S8). Overall, there were more negative associations for richness, evenness and phylogenetic diversity with seven fungi (Wickerhamomyces, Starmerella, Meyerozyma, inter alia) and only two fungi (Saccharomyces and Agaricomycetes spp) with positive associations. Thus, gut fungi may have the potential to manipulate neighbouring bacterial communities or vice versa.
We hypothesised that gut fungi may be more related to bacterial gene function rather than taxonomy. Based on the metagenomics sequencing, the bacterial Kyoto Encyclopaedia of Genes and Genomes orthologues (KOs) were profiled using HUMAnN2 to assess the associations between core fungal taxa and the gene functions of gut bacteria. The KOs associated with the mycobiome were most enriched in metabolic pathways, followed by the biosynthesis of secondary metabolites and microbial metabolism in diverse environments, which indicates the potential ways of cross-kingdom communication between gut fungi and bacteria (q<0.05, figure 3B). When the KOs were mapped into the Brite hierarchical topologies, most of the significant KOs represented the bacterial enzymes, transporters, secretion systems and transcription factors. Interestingly, Saccharomycetales spp (unclassified genus) had the highest number (170) of associations with bacterial functions, but this taxon only had three significant associations with bacterial taxa (figure 3B and online supplemental tables S10 and S11).
Gut mycobiome and the faecal metabolome
As with cross-kingdom associations, examining the faecal metabolites that were associated with gut mycobiome could facilitate mechanistic insight into the gut ecosystem. The absolute concentrations of 198 metabolites were targeted measured using the UPLC-MS/MS system in 913 participants. The Procrustes analysis demonstrated a strong cooperativity of the gut mycobiome and faecal metabolome (online supplemental figure S9A). There were 110 associations identified involving 13 gut fungi and 82 faecal metabolites that were significant at a 5% FDR (figure 4A and online supplemental table S12). Notably, about 60% bile acids (15 out of 25) were significantly associated with Wickerhamiella (figure 4B). For instance, Wickerhamiella was positively associated with chenodeoxycholic acid, cholic acid and glycochenodexycholic acid (q<0.01). Saccharomyces was positively associated with decanoic acid which is a medium-chain saturated fatty acid with antibacterial and an anti-inflammatory role (Spearman’s rho=0.18, q<0.001). Intriguingly, all these metabolites were associated with various fungi-related KOs (online supplemental table S13), which might support an interpretation of gut mycobiome and bacterial codependence or functional synergism.
To further use faecal metabolite information in the understanding of gut mycobiomic composition and variation, correlation analyses between the abundances of faecal metabolites and gut fungal community characteristics were conducted. Overall, 47 faecal metabolites were associated with the fungal structure at p<0.05 (PERMANOVA, q<0.2; figure 4B). Among these metabolites, more than a quarter (13 out of 47) were fatty acids. The major contributors to the variance of the whole gut mycobiome were 3-methyladipic acid, tridecanoic acid and ethylmethylacetic acid. In addition, more than half (25 out of 47) of the above faecal metabolites were also associated with specific fungal taxa, such as carnosine, D-gluconolactone and L-threonine (online supplemental figure S9B). This permits a speculation that the faecal metabolites may play an elaborate role in the cross-talk between gut fungi, bacteria and general host biology with health implications.
Pathways from gut mycobiome to metabolic health
We sought to explore the potential relevance of the human gut mycobiome to metabolic health by performing two linear regression models (see online supplemental methods). These models were performed between 26 core fungi and 11 metabolic risk factors adjusted for age and gender. Accordingly, 12 nominally significant associations from the abundance-based models and 26 from the presence-based models were identified (p<0.05, figure 5A and online supplemental table S14). For example, we observed that the relative abundance of Penicillium was positively associated with fasting glucose, and the presence of Malassezia and Kazachstania was positively associated with fasting glucose and waist circumference, respectively. These findings were replicated in the independent replication cohort (figure 5A, online supplemental figure S10 and online supplemental table S15). Notably, the relative abundance of Saccharomyces was inversely associated with fasting glucose but positively associated with high-density lipoprotein cholesterol (figure 5A), suggesting that Saccharomyces might be a beneficial fungal taxon for human metabolic health. In line with this, an animal study showed that Saccharomyces boulardii could reduce blood glucose and triglycerides in mice with diabetes.24 Even so, none of the direct associations surpassed the conservative threshold of q<0.05.
We hypothesised that the gut mycobiome could modify the associations between bacterial α-diversity and metabolic health. With a linear regression model, we explored the interaction of core fungal taxa with bacterial α-diversity indices on the metabolic traits. Three significant interactions were observed repeatedly in the replication cohort (figure 5B and online supplemental figure S10). A noteworthy example was the significant interaction of Saccharomycetales spp with bacterial α-diversity on homeostatic model assessment of insulin resistance (HOMA-IR) (p value for interaction <0.05, figure 5B), as well as insulin (online supplemental figure S11A). Per 1 SD difference in the Shannon index was associated with a lower HOMA-IR only among individuals with Saccharomycetales spp but not those without this fungus. Intriguingly, changes in the relative abundance of this fungus between baseline and follow-up were also inversely associated with parallel changes in total and low-density lipoprotein (LDL) cholesterol (p<0.05, online supplemental table S16).
To further understand the potential mechanisms of the aforementioned interactions, we looked for associations between Saccharomycetales spp, bacterial taxa and short-chain fatty acids (SCFAs). SCFAs are gut bacteria-derived metabolites, produced in the host as energy substrates for the colonic epithelium and peripheral tissues, that can be a pathway to metabolic disorders.25 We observed that Saccharomycetales spp had a positive association with Clostridium sensu stricto 1, Faecalitalea and Megamonas (p<0.05, figure 5C). All these bacterial taxa are SCFA producers.26–28 Consistent with this, Saccharomycetales spp was positively associated with acetic acid and butyric acid (p<0.008, online supplemental table S12). Nevertheless, more mechanistic work is needed to understand the relationship among gut Saccharomycetales spp, bacteria, SCFAs and glucose homeostasis.
To evaluate whether gut bacterial function can mediate the fungal impact on host metabolic health, bidirectional mediation analysis was conducted using baseline gut mycobiome and fungi-related bacterial KOs/faecal metabolites, together with any longitudinal change of host phenotypes between baseline and follow-up visit. This showed that the presence of Pichia probably contributed to a decrease in LDL cholesterol by increasing the bacterial functional levels, such as exoribonuclease II (K01147), deoxyribodipyrimidine photolyase-related protein (K06876) and putative hemin transport protein (hmuS, K07225) (all pmediation <0.007, figure 6). Specifically, hmuS protein levels explained 26% of the total effect of Pichia on LDL cholesterol, while the inverse mediation analyses revealed that hmuS could not influence the LDL cholesterol levels through Pichia. We also found that Pichia may decrease the total cholesterol levels through faecal histidine (pmediation <0.05, online supplemental figure S12). Of interest in ageing biology, the positive association between the Saccharomycetales spp and Pichia decreased from middle age to later life (online supplemental figure S13A). Support for the biological meaningfulness of this finding comes from the longitudinal data where this concurrence weakened from baseline to the follow-up visit (online supplemental figure S13B). Taken together, these findings represent gut mycobiome interactions by gut bacterial taxonomy and function relevant to metabolic health.
Discussion
This work depicts the gut mycobiome in a broad microbiomic context, for an ethnogeographically defined cohort defined by age, long-term habitual diet and physiological status. Ascomycetes were the dominant group of gut fungi and temporally stable even after 3.2 years. Interactions were identified between the gut mycobiota and bacterial α-diversity in relation to metabolic health, which could be replicated in an independent cohort. Of indicative and metabolic interest, Pichia may influence LDL cholesterol through specific bacterial functions.
Previous research has shown that Ascomycota and Basidiomycota are two dominant phyla in the GI tract, which is consistent with our findings.7 The present study identified 26 core fungal taxa, 8 of which have been listed as the most commonly detected fungi in gut mycobiomic studies,29 including Candida, Saccharomyces, Penicillium, Aspergillus, Malassezia, Cladosporium, Debaryomyces and Trichosporon.30 Notably, we found through literature review that these gut fungal genera have various environmental counterparts which indicate the potential origins or sources of the fungi and reflect that human health may be inherently affected by the environments that we traverse. Many fungal taxa displayed long-term stability even after 3.2 years in 184 participants, indicative of a core mycobiome, within its total. A fundamental question is which fungi are truly colonising the human gut? In 2018, a study in 100 healthy individuals argued that fungi do not routinely colonised the GI tracts of healthy adults.31 However, core fungal taxa were identified in the present study and could be observed at both time points in the discovery and replication cohort over 3 years apart. We also found some fungi were temporally stable in the same individual. It seems that the gut mycobiome may play a role in the long-term stability of the gut ecosystem. To our knowledge, the present study is the first investigation into the difference in gut mycobiome between the elderly and younger individuals. We not only found that Blastobotrys was decreased from baseline to follow-up longitudinally, but also revealed that this genus had a depletion in the elderly compared with the middle-aged individuals cross-sectionally. Blastobotrys adeninivorans can assimilate a wide spectrum of carbon and nitrogen sources, which makes it a dominant yeast in the fermentation of Pu-erh tea.32 Further studies are needed for a more comprehensive profiling of mycobial alterations through the full human life cycle.
The influence of diet on human gut mycobiome composition, and in association with the bacterial microbiome, appears likely, extensive and complex, especially for specific food categories.11 33 Previous work has shown that long-term habitual dairy consumption is associated with a higher bacterial α-diversity.34 Interestingly, dairy consumption made the largest contribution to the variation of fungal community among the 16 food categories in our study. Moreover, dairy consumption was positively associated with Saccharomyces but inversely associated with Candida. Previous studies reveal anti-inflammatory effects of Saccharomyces 35 36, which were negatively associated with the Framingham 10-year risk score.21 However, some species of Candida can infect humans, such as Candida albicans 37 and C. parapsilosis.38 We found that bacterial α-diversity was positively associated with Saccharomyces and negatively associated with Candida. Whether coherent with this or not, gut bacterial α-diversity seems to be a good indicator of a ‘healthy gut’.39 Perhaps dairy consumption contributes to a healthier diet in terms of gut ecohealth by modulating gut microbial relationships.
We have comprehensively analysed the ecological connections between gut fungi and bacteria. There are broad associations between gut fungi and bacterial taxa, gene functions and functional products, that is, metabolites, to be found in our study. Specifically, the human gut mycobiome is closely related to various metabolic pathways and the biosynthesis of secondary metabolites by bacteria. Moreover, since fungal signalling may be via volatile organic compounds (VOCs), recognition and diagnosis of such phenomena may be more successful with exhaled breath than with faecal tests.40 Saccharomyces was positively associated with decanoic acid (capric acid). This metabolite is a VOC fatty acid which can be produced by S. boulardii.41 It exemplifies many ecological interactions involving fungi mediated by VOCs.42 Decanoic acid can, in turn, modulate fatty acid biosynthesis by bacteria.43 Given the likely underestimation of gut microbial VOC physiology, its pursuance should be worthwhile.
Microbiomic ecology is fundamental for the optimisation of human health, for which Saccharomycetales spp is proving an exemplar.44 There is a significant interaction with Saccharomycetales spp for bacterial α-diversity on HOMA-IR. The lower value of HOMA-IR indicated a higher degree of insulin sensitivity.45 In a population-based cohort study, bacterial α-diversity measures were lower among participants with higher measures of HOMA-IR in both the NFBC1966 cohort (n=506) and in the Twins UK cohort (n=1140).46 This is in line with the present study among the Saccharomycetales spp carriers. SCFAs are used as energy sources, contributing to the whole-body energy metabolism and glucose homeostasis.25 47 Because of the positive associations between the Saccharomycetales spp and SCFA producers, the bacterial community should have more potential to produce SCFAs and increase insulin sensitivity in Saccharomycetales spp carriers. The wide associations between gut mycobiota and bacterial biosynthesis of secondary metabolites support such a hypothesis. In addition, the mediation analyses indicate that gut bacterial function can mediate fungal effects on host metabolic health. The elevated LDL cholesterol is a major cause of cardiovascular diseases.48 49 Madeeha et al demonstrated that Pichia kudriavzevii had cholesterol assimilation capability ranging from 66.7% to 80.4% after 72 hours of incubation at 37°C.50 Here, Pichia may modulate cholesterol turnover through the interaction with bacterial function and faecal histidine. The present observational findings need the support of intervention studies for confirmation. In the meantime, this is an example of how integrative cross-kingdom microbiomics might open novel opportunities to address metabolic disease risk and management.
The present study has limitations. First, the findings may or may not be extrapolatable to other ethnicity groups. Second, the study is observational, and associations are not proof of causation. Nevertheless, the multiomics and longitudinal analyses (with causal mediation analyses) can infer potential causality and improve ecobiological understanding, amenable to experimental pursuit.
Conclusion
These findings show that the gut mycobiome is an essential component of the gut ecosystem, interactive with the bacterial community and contribute to the overall human metabolic health.
Acknowledgments
We thank all study participants of the Guangzhou Nutrition and Health Study. We thank Westlake University Supercomputer Centre for assistance in data storage and computation. We acknowledge the support from Westlake Education Foundation and Westlake Intelligent Biomarker Discovery Lab at the Westlake Laboratory of Life Sciences and Biomedicine. We thank Guoqing Zhang for valuable discussion.
Footnotes
Twitter: @TienHuynhAU, @Ju-Sheng Zheng@zheng_jusheng
MS, YF and H-lZ contributed equally.
Contributors: J-SZ, MLW and YC designed the study; H-LZ, J-JX, YL and ZM collected the data; MS and YF performed the data analysis; YF, ZJ, WG, TH and MLW contributed to the discussion; MS, YC and J-SZ drafted the manuscript; J-SZ, MLW and TH revised the manuscript; all authors read, revised and approved the final manuscript. J-SZ acts as guarantor for this study and publication.
Funding: This work was supported by the National Natural Science Foundation of China (82073529, 81903316, 81773416 and 82103826); Zhejiang Ten-thousand Talents Program (2019R52039); Westlake Multidisciplinary Research Initiative Centre (MRIC20200301); the Zhejiang Provincial Natural Science Foundation of China (LQ21H260002); the China Postdoctoral Science Foundation (2020M681945); and the 5010 Programme for Clinical Research (2007032) of the Sun Yat-sen University (Guangzhou, China). The funders were not involved in the study design, implementation, analysis or interpretation of data.
Competing interests: None declared.
Provenance and peer review: Not commissioned; externally peer reviewed.
Supplemental material: This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.
Data availability statement
Data are available in a public, open access repository. The raw data of the ITS2 sequencing, 16S rRNA sequencing and metagenomic sequencing are available in the CNSA (https://db.cngb.org/cnsa/) of CNGBdb (accession number CNP0002114, CNP0000829 and CNP0001510, respectively). Other data sets generated during and/or analysed during the current study are available from the corresponding author upon reasonable request.
Ethics statements
Patient consent for publication
Not applicable.
Ethics approval
This study involves human participants and was approved by the ethics committees of the School of Public Health at Sun Yat-sen University (2018048) and Westlake University (20190114ZJS0003). Participants gave informed consent to participate in the study before taking part.
References
- 1. James TY, Kauff F, Schoch CL, et al. Reconstructing the early evolution of fungi using a six-gene phylogeny. Nature 2006;443:818–22. 10.1038/nature05110 [DOI] [PubMed] [Google Scholar]
- 2. Blackwell M, Evolution BM. Evolution. Terrestrial life--fungal from the start? Science 2000;289:1884–5. 10.1126/science.289.5486.1884 [DOI] [PubMed] [Google Scholar]
- 3. Zheng J-S, Wahlqvist ML. Regulobiosis: a regulatory and food system-sensitive role for fungal symbionts in human evolution and ecobiology. Asia Pac J Clin Nutr 2020;29:9–15. 10.6133/apjcn.202003_29(1).0002 [DOI] [PubMed] [Google Scholar]
- 4. Wahlqvist ML. Ecosystem dependence of healthy localities, food and people. Annals of Nutrition and Metabolism 2016;69:75–8. 10.1159/000449143 [DOI] [PubMed] [Google Scholar]
- 5. Mukherjee PK, Sendid B, Hoarau G, et al. Mycobiota in gastrointestinal diseases. Nat Rev Gastroenterol Hepatol 2015;12:77–87. 10.1038/nrgastro.2014.188 [DOI] [PubMed] [Google Scholar]
- 6. Fiers WD, Leonardi I, Iliev ID. From birth and throughout life: fungal microbiota in nutrition and metabolic health. Annu Rev Nutr 2020;40:323–43. 10.1146/annurev-nutr-013120-043659 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Richard ML, Sokol H. The gut mycobiota: insights into analysis, environmental interactions and role in gastrointestinal diseases. Nat Rev Gastroenterol Hepatol 2019;16:331–45. 10.1038/s41575-019-0121-2 [DOI] [PubMed] [Google Scholar]
- 8. Huffnagle GB, Noverr MC. The emerging world of the fungal microbiome. Trends Microbiol 2013;21:334–41. 10.1016/j.tim.2013.04.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Coker OO, Nakatsu G, Dai RZ, et al. Enteric fungal microbiota dysbiosis and ecological alterations in colorectal cancer. Gut 2019;68:654–62. 10.1136/gutjnl-2018-317178 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Sun Y, Zuo T, Cheung CP, et al. Sa1915 population-level configurations of gut MYCOBIOME across six ethnicities in urban and rural China. Gastroenterology 2020;158:S-478–S-479. 10.1016/S0016-5085(20)31874-6 [DOI] [PubMed] [Google Scholar]
- 11. Hoffmann C, Dollive S, Grunberg S, et al. Archaea and fungi of the human gut microbiome: correlations with diet and bacterial residents. PLoS One 2013;8:e66019. 10.1371/journal.pone.0066019 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Nash AK, Auchtung TA, Wong MC, et al. The gut mycobiome of the human microbiome project healthy cohort. Microbiome 2017;5:153. 10.1186/s40168-017-0373-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Strati F, Di Paola M, Stefanini I, et al. Age and gender affect the composition of fungal population of the human gastrointestinal tract. Front Microbiol 2016;7:1227. 10.3389/fmicb.2016.01227 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Qin J, Li Y, Cai Z, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 2012;490:55–60. 10.1038/nature11450 [DOI] [PubMed] [Google Scholar]
- 15. Jose PA, Raj D. Gut microbiota in hypertension. Curr Opin Nephrol Hypertens 2015;24:403–9. 10.1097/MNH.0000000000000149 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16. Turnbaugh PJ, Hamady M, Yatsunenko T, et al. A core gut microbiome in obese and lean twins. Nature 2009;457:480–4. 10.1038/nature07540 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Deveau A, Bonito G, Uehling J, et al. Bacterial-fungal interactions: ecology, mechanisms and challenges. FEMS Microbiol Rev 2018;42:335–52. 10.1093/femsre/fuy008 [DOI] [PubMed] [Google Scholar]
- 18. Kim D-H, Kim H, Jeong D, et al. Kefir alleviates obesity and hepatic steatosis in high-fat diet-fed mice by modulation of gut microbiota and mycobiota: targeted and untargeted community analysis with correlation of biomarkers. J Nutr Biochem 2017;44:35–43. 10.1016/j.jnutbio.2017.02.014 [DOI] [PubMed] [Google Scholar]
- 19. Mims TS, Abdallah QA, Stewart JD, et al. The gut mycobiome of healthy mice is shaped by the environment and correlates with metabolic outcomes in response to diet. Commun Biol 2021;4:281. 10.1038/s42003-021-01820-z [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. Mar Rodríguez M, Pérez D, Javier Chaves F, et al. Obesity changes the human gut mycobiome. Sci Rep 2015;5:14600. 10.1038/srep14600 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. Chacón MR, Lozano-Bartolomé J, Portero-Otín M, et al. The gut mycobiome composition is linked to carotid atherosclerosis. Benef Microbes 2018;9:185–98. 10.3920/BM2017.0029 [DOI] [PubMed] [Google Scholar]
- 22. Ahmad HF, Ahmad HF, Mejia JLC, et al. Gut Mycobiome dysbiosis is linked to hypertriglyceridemia among home Dwelling elderly Danes. bioRxiv 2020. 10.1101/2020.04.16.044693 [DOI] [Google Scholar]
- 23. Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010;464:59–65. 10.1038/nature08821 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24. BRANDÃO ANABP, de Abreu IC, Aimbire F. Saccharomyces boulardii attenuates autonomic cardiovascular dysfunction and modulates inflammatory cytokines in diabetic mice. Diabetes 2018;67. 10.2337/db18-2365-PUB [DOI] [Google Scholar]
- 25. den Besten G, van Eunen K, Groen AK, et al. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J Lipid Res 2013;54:2325–40. 10.1194/jlr.R036012 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26. Appert O, Garcia AR, Frei R, et al. Initial butyrate producers during infant gut microbiota development are endospore formers. Environ Microbiol 2020;22:3909–21. 10.1111/1462-2920.15167 [DOI] [PubMed] [Google Scholar]
- 27. De Maesschalck C, Van Immerseel F, Eeckhaut V, et al. Faecalicoccus acidiformans gen. nov., sp. nov., isolated from the chicken caecum, and reclassification of Streptococcus pleomorphus (Barnes et al. 1977), Eubacterium biforme (Eggerth 1935) and Eubacterium cylindroides (Cato et al. 1974) as Faecalicoccus pleomorphus comb. nov., Holdemanella biformis gen. nov., comb. nov. and Faecalitalea cylindroides gen. nov., comb. nov., respectively, within the family Erysipelotrichaceae. Int J Syst Evol Microbiol 2014;64:3877–84. 10.1099/ijs.0.064626-0 [DOI] [PubMed] [Google Scholar]
- 28. Sakon H, Nagai F, Morotomi M, et al. Sutterella parvirubra sp. nov. and Megamonas funiformis sp. nov., isolated from human faeces. Int J Syst Evol Microbiol 2008;58:970–5. 10.1099/ijs.0.65456-0 [DOI] [PubMed] [Google Scholar]
- 29. Hallen-Adams HE, Suhr MJ. Fungi in the healthy human gastrointestinal tract. Virulence 2017;8:352–8. 10.1080/21505594.2016.1247140 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30. Naranjo-Ortiz MA, Gabaldón T. Fungal evolution: diversity, taxonomy and phylogeny of the fungi. Biol Rev Camb Philos Soc 2019;94:2101–37. 10.1111/brv.12550 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31. Auchtung TA, Fofanova TY, Stewart CJ, et al. Investigating colonization of the healthy adult gastrointestinal tract by fungi. mSphere 2018;3:ARTN e00092. 10.1128/mSphere.00092-18 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32. Tian F, Shi J, Li Y, et al. Proteogenomics Study of Blastobotrys adeninivorans TMCC 70007—A Dominant Yeast in the Fermentation Process of Pu-erh Tea. J Proteome Res 2021;20:3290–304. 10.1021/acs.jproteome.1c00205 [DOI] [PubMed] [Google Scholar]
- 33. Ukhanova M, Wang X, Baer DJ, et al. Effects of almond and pistachio consumption on gut microbiota composition in a randomised cross-over human feeding study. Br J Nutr 2014;111:2146–52. 10.1017/S0007114514000385 [DOI] [PubMed] [Google Scholar]
- 34. Shuai M, Zuo L-S-Y, Miao Z, et al. Multi-Omics analyses reveal relationships among dairy consumption, gut microbiota and cardiometabolic health. EBioMedicine 2021;66:103284. 10.1016/j.ebiom.2021.103284 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35. Thomas S, Metzke D, Schmitz J, et al. Anti-Inflammatory effects of Saccharomyces boulardii mediated by myeloid dendritic cells from patients with Crohn's disease and ulcerative colitis. Am J Physiol Gastrointest Liver Physiol 2011;301:G1083–92. 10.1152/ajpgi.00217.2011 [DOI] [PubMed] [Google Scholar]
- 36. Rodríguez-Nogales A, Algieri F, Garrido-Mesa J, et al. Intestinal anti-inflammatory effect of the probiotic Saccharomyces boulardii in DSS-induced colitis in mice: impact on microRNAs expression and gut microbiota composition. J Nutr Biochem 2018;61:129–39. 10.1016/j.jnutbio.2018.08.005 [DOI] [PubMed] [Google Scholar]
- 37. Kim J, Sudbery P. Candida albicans, a major human fungal pathogen. J Microbiol. 2011;49:171–7. 10.1007/s12275-011-1064-7 [DOI] [PubMed] [Google Scholar]
- 38. Trofa D, Gácser A, Nosanchuk JD. Candida parapsilosis, an emerging fungal pathogen. Clin Microbiol Rev 2008;21:606–25. 10.1128/CMR.00013-08 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39. Valdes AM, Walter J, Segal E, et al. Role of the gut microbiota in nutrition and health. BMJ 2018;361:k2179. 10.1136/bmj.k2179 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40. Nakhleh MK, Amal H, Jeries R, et al. Diagnosis and Classification of 17 Diseases from 1404 Subjects via Pattern Analysis of Exhaled Molecules. ACS Nano 2017;11:112–25. 10.1021/acsnano.6b04930 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41. Murzyn A, Krasowska A, Stefanowicz P, et al. Capric acid secreted by S. boulardii inhibits C. albicans filamentous growth, adhesion and biofilm formation. PLoS One 2010;5:e12050. 10.1371/journal.pone.0012050 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42. Morath SU, Hung R, Bennett JW. Fungal volatile organic compounds: a review with emphasis on their biotechnological potential. Fungal Biol Rev 2012;26:73–83. 10.1016/j.fbr.2012.07.001 [DOI] [Google Scholar]
- 43. Sado-Kamdem SL, Vannini L, Guerzoni ME. Effect of α-linolenic, capric and lauric acid on the fatty acid biosynthesis in Staphylococcus aureus. Int J Food Microbiol 2009;129:288–94. 10.1016/j.ijfoodmicro.2008.12.010 [DOI] [PubMed] [Google Scholar]
- 44. Godoy-Vitorino F. Human microbial ecology and the rising new medicine. Ann Transl Med 2019;7:342. 10.21037/atm.2019.06.56 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45. Vogeser M, König D, Frey I, et al. Fasting serum insulin and the homeostasis model of insulin resistance (HOMA-IR) in the monitoring of lifestyle interventions in obese persons. Clin Biochem 2007;40:964–8. 10.1016/j.clinbiochem.2007.05.009 [DOI] [PubMed] [Google Scholar]
- 46. Zouiouich S, Loftfield E, Huybrechts I, et al. Markers of metabolic health and gut microbiome diversity: findings from two population-based cohort studies. Diabetologia 2021;64:1749–59. 10.1007/s00125-021-05464-w [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47. Puddu A, Sanguineti R, Montecucco F, et al. Evidence for the gut microbiota short-chain fatty acids as key pathophysiological molecules improving diabetes. Mediators Inflamm 2014;2014:1–9. 10.1155/2014/162021 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48. Ference BA, Ginsberg HN, Graham I, et al. Low-Density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis Society consensus panel. Eur Heart J 2017;38:2459–72. 10.1093/eurheartj/ehx144 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41:111–88. 10.1093/eurheartj/ehz455 [DOI] [PubMed] [Google Scholar]
- 50. Madeeha IR, Ikram A, Imran M. A preliminary insight of correlation between human fecal microbial diversity and blood lipid profile. Int J Food Sci Nutr 2016;67:865–71. 10.1080/09637486.2016.1201791 [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
gutjnl-2021-326298supp001.pdf (3MB, pdf)
gutjnl-2021-326298supp002.xlsx (1.3MB, xlsx)
Data Availability Statement
Data are available in a public, open access repository. The raw data of the ITS2 sequencing, 16S rRNA sequencing and metagenomic sequencing are available in the CNSA (https://db.cngb.org/cnsa/) of CNGBdb (accession number CNP0002114, CNP0000829 and CNP0001510, respectively). Other data sets generated during and/or analysed during the current study are available from the corresponding author upon reasonable request.